PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

Linda Vidarsdottir; Alireza Azimi; Ishani Das; Ingibjorg Sigvaldadottir; Aldwin Suryo Rahmanto; Andreas Petri; Sakari Kauppinen; Christian Ingvar; Göran Jönsson; Håkan Olsson; Marianne Frostvik Stolt; Rainer Tuominen; Olle Sangfelt; Katja Pokrovskaja Tamm; Johan Hansson; Dan Grandér; Suzanne Egyházi Brage; Per Johnsson

doi:10.1038/s41598-021-89389-9

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

Linda Vidarsdottir, Alireza Azimi, Ishani Das, Ingibjorg Sigvaldadottir, Aldwin Suryo Rahmanto, Andreas Petri, Sakari Kauppinen, Christian Ingvar, Göran Jönsson, Håkan Olsson, Marianne Frostvik Stolt, Rainer Tuominen, Olle Sangfelt, Katja Pokrovskaja Tamm, Johan Hansson, Dan Grandér, Suzanne Egyházi Brage^*, Per Johnsson^*

^*Kontaktforfatter

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

2 Downloads (Pure)

Originalsprog	Engelsk
Artikelnummer	11023
Tidsskrift	Scientific Reports
Vol/bind	11
Udgave nummer	1
Antal sider	11
ISSN	2045-2322
DOI	https://doi.org/10.1038/s41598-021-89389-9
Status	Udgivet - 26 maj 2021

Adgang til dokumentet

10.1038/s41598-021-89389-9Licens: CC BY 4.0

Vidarsdottir et al. (2021). PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanomaForlagets udgivne version, 1,13 MBLicens: CC BY 4.0

Andre filer og links

Link to publication in Scopus

Citationsformater

Vidarsdottir, L., Azimi, A., Das, I., Sigvaldadottir, I., Suryo Rahmanto, A., Petri, A., Kauppinen, S., Ingvar, C., Jönsson, G., Olsson, H., Frostvik Stolt, M., Tuominen, R., Sangfelt, O., Pokrovskaja Tamm, K., Hansson, J., Grandér, D., Egyházi Brage, S., & Johnsson, P. (2021). PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma. Scientific Reports, 11(1), [11023]. https://doi.org/10.1038/s41598-021-89389-9

Vidarsdottir, Linda ; Azimi, Alireza ; Das, Ishani ; Sigvaldadottir, Ingibjorg ; Suryo Rahmanto, Aldwin ; Petri, Andreas ; Kauppinen, Sakari ; Ingvar, Christian ; Jönsson, Göran ; Olsson, Håkan ; Frostvik Stolt, Marianne ; Tuominen, Rainer ; Sangfelt, Olle ; Pokrovskaja Tamm, Katja ; Hansson, Johan ; Grandér, Dan ; Egyházi Brage, Suzanne ; Johnsson, Per. / PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma. I: Scientific Reports. 2021 ; Bind 11, Nr. 1.

@article{4126c388b76b418bbab9cd4b3824935b,

title = "PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma",

author = "Linda Vidarsdottir and Alireza Azimi and Ishani Das and Ingibjorg Sigvaldadottir and {Suryo Rahmanto}, Aldwin and Andreas Petri and Sakari Kauppinen and Christian Ingvar and G{\"o}ran J{\"o}nsson and H{\aa}kan Olsson and {Frostvik Stolt}, Marianne and Rainer Tuominen and Olle Sangfelt and {Pokrovskaja Tamm}, Katja and Johan Hansson and Dan Grand{\'e}r and {Egyh{\'a}zi Brage}, Suzanne and Per Johnsson",

year = "2021",

month = may,

day = "26",

doi = "10.1038/s41598-021-89389-9",

language = "English",

volume = "11",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

number = "1",

}

Vidarsdottir, L, Azimi, A, Das, I, Sigvaldadottir, I, Suryo Rahmanto, A, Petri, A , Kauppinen, S, Ingvar, C, Jönsson, G, Olsson, H, Frostvik Stolt, M, Tuominen, R, Sangfelt, O, Pokrovskaja Tamm, K, Hansson, J, Grandér, D, Egyházi Brage, S & Johnsson, P 2021, 'PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma', Scientific Reports, bind 11, nr. 1, 11023. https://doi.org/10.1038/s41598-021-89389-9

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma. / Vidarsdottir, Linda; Azimi, Alireza; Das, Ishani; Sigvaldadottir, Ingibjorg; Suryo Rahmanto, Aldwin; Petri, Andreas ; Kauppinen, Sakari; Ingvar, Christian; Jönsson, Göran; Olsson, Håkan; Frostvik Stolt, Marianne; Tuominen, Rainer; Sangfelt, Olle; Pokrovskaja Tamm, Katja; Hansson, Johan; Grandér, Dan; Egyházi Brage, Suzanne; Johnsson, Per.

I: Scientific Reports, Bind 11, Nr. 1, 11023, 26.05.2021.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

TY - JOUR

T1 - PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

AU - Vidarsdottir, Linda

AU - Azimi, Alireza

AU - Das, Ishani

AU - Sigvaldadottir, Ingibjorg

AU - Suryo Rahmanto, Aldwin

AU - Petri, Andreas

AU - Kauppinen, Sakari

AU - Ingvar, Christian

AU - Jönsson, Göran

AU - Olsson, Håkan

AU - Frostvik Stolt, Marianne

AU - Tuominen, Rainer

AU - Sangfelt, Olle

AU - Pokrovskaja Tamm, Katja

AU - Hansson, Johan

AU - Grandér, Dan

AU - Egyházi Brage, Suzanne

AU - Johnsson, Per

PY - 2021/5/26

Y1 - 2021/5/26

UR - http://www.scopus.com/inward/record.url?scp=85106901248&partnerID=8YFLogxK

U2 - 10.1038/s41598-021-89389-9

DO - 10.1038/s41598-021-89389-9

M3 - Journal article

C2 - 34040017

VL - 11

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 11023

ER -

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater